<DOC>
	<DOCNO>NCT02368652</DOCNO>
	<brief_summary>Compare safety efficacy amlodipine besylate candesartan cilexetil combination therapy patient essential hypertension properly control candesartan cilexetil monotherapy .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Amlodipine Besylate Candesartan Cilexetil Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Male female age ≥ 19 ≤ 75 year old Subject essential hypertension Subject voluntarily agree participate trial sign write informed consent form , listen purpose , method , effect clinical trial Subject siDBP ≥ 120 mmHg siSBP ≥ 200 mmHg Visit 1 ( screen ) Subject difference mean blood pressure 10 mmHg siDBP 20 mmHg siSBP arm screen visit Subject know suspect secondary hypertension [ Including limit follow : renovascular disease , adrenal medullary cortical hyperfunctions , coarctation aorta , primary hyperaldosteronism , unilateral bilateral renal artery stenosis , Cushing 's syndrome , pheochromocytoma , polycystic kidney disease , etc . ] Subject symptomatic orthostatic hypotension ( sudden fall siDBP least 10 mmHg siSBP least 20 mmHg standing compare blood pressure sit supin position ) Subject type 1 type 2 diabetes mellitus poor glucose control ( define subject inculin treatment , HbA1c &gt; 9.0 % modification oral antihyperglycemic medication regiment within past 12 week prior visit 1 ) Subject severe heart disease ( congestive heart failure ( NYHA class 3 4 ) , ischemic heart disease within past 6 month ( unstable angina , myocardial infarction ) , peripheral blood vascula disease , history Percutaneous Transluminal Coronary Angioplasty coronary artery bypass graft ) Subject clinically significant ventricular tachycardia , atrial fibrillation , atrial flutter clinically significant arrhythmia Subject hypertrophic obstructive cardiomyopathy , severe obstructive coronary artery disease , aortic stenosis , haemodynamically relevant stenosis aortic mitral valve Subject cardiogenic shock Subject severe cerebrovascular disease ( history stroke , cerebral infraction , cerebral hemorrhage within past 6 month ) Subject history ongoing waste disease , autoimmune disease ( rheumatoid arthritis , systemic lupus erythematosus , etc . ) connective tissue disease Subject know moderate malignant retinopathy ( history retinal sign hemorrhage , visual impairment , retinal microaneurysm etc . within past 6 month ) Subject surgical medical condition gastrointestinal tract might sugnificantly alter absorption , distribution , metabolism excretion drug Subject history malignant tumor include leukemia lymphoma within past 5 yesrs ( except localize basal cell carcinoma skin ) Subject chronic inflammatory condition need chronic antiinflammatory therapy Subject chronic kidney disase dialysis Subject follow clinically significant laboratory abnormality : AST ALT &gt; 3 x Upper Limit Normal ( ULN ) Serum Creatinine &gt; 1.5 ULN Serum potassium &lt; 3.5 mmol/L &gt; 5.5mmol/L Subject require concomitant use antihypertensive contraindicate drug entire study period Subject know suspected contraindication , include history allergy hypersensitivity ARB dihydropyridine derivative Subject previously experience symptom characteristic angioedema treatment ACE inhibitor ARB Pregnant woman lactate mother , woman suspect pregnant , woman wish pregnant study woman childbearing potential use medically acceptable method contraception ( oral contraceptinve , intrauterine device , condom , etc . ) , except woman surgical sterilization . Premenopausal woman surgically sterilize must negative pregnancy test result Visit1 maintain acceptable method contraception throughout study . preiodic abstinence ( eg . symptothermal , calendar , postovulation method ) , hormonal contraceptive acceptable method contraception History drug alcohol abuse within past 1 year Use investigational product within past 4 week Subject jdged unsuitable participate study opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>